Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- ampicillin / probenecid
- baricitinib
Interactions between your drugs
probenecid baricitinib
Applies to: ampicillin / probenecid, baricitinib
ADJUST DOSE: Coadministration with potent inhibitors of organic anion transporter 3 (OAT3) may decrease the renal clearance and increase the plasma concentrations of baricitinib, which has been shown in vitro to be a substrate of the transporter. In healthy study subjects, administration of a single 4 mg dose of baricitinib following treatment with multiple twice daily dosing of 1000 mg probenecid, a potent OAT3 inhibitor, resulted in an approximately 70% decrease in baricitinib renal clearance and 2-fold increase in systemic exposure (AUC), with no effect on peak plasma concentration (Cmax) or time to reach peak plasma concentration (Tmax). No clinical pharmacology study has been conducted with OAT3 inhibitors with less inhibition potential. However, simulations with diclofenac and ibuprofen (less potent OAT3 inhibitors) predicted minimal effect on the pharmacokinetics of baricitinib.
MANAGEMENT: The dosage of baricitinib should be reduced by one-half during coadministration with potent OAT3 inhibitors as follows: (1) If the recommended dosage is 4 mg once daily, reduce to 2 mg once daily; (2) If the recommended dosage is 2 mg once daily, reduce to 1 mg once daily; (3) If the recommended dosage is 1 mg once daily, consider discontinuing the OAT3 inhibitor. Patients should be monitored for adverse effects of baricitinib such as infections, malignancies, thrombosis, hematologic abnormalities, gastrointestinal perforations, hyperlipidemia, and hepatic transaminase elevations.
References (4)
- (2023) "Product Information. Olumiant (baricitinib)." Lilly, Eli and Company, DailyMed
- (2023) "Product Information. Olumiant (bARICITinib)." Eli Lilly Australia Pty Ltd, vA9.0_May2023
- (2024) "Product Information. Olumiant (baricitinib)." Eli Lilly and Company Ltd
- (2024) "Product Information. Olumiant (baricitinib)." Eli Lilly Canada Inc, 270684
ampicillin probenecid
Applies to: ampicillin / probenecid, ampicillin / probenecid
Probenecid may increase the plasma concentrations and half-lives of penicillins. The mechanism is competitive inhibition by probenecid of the renal tubular secretion of penicillins. While this interaction is often exploited to enhance the antibacterial effect of penicillins, toxicity may occur and should be considered if high penicillin dosages are administered intravenously.
References (6)
- Sommers DK, Schoeman HS (1987) "Drug interactions with urate excretion in man?" Eur J Clin Pharmacol, 32, p. 499-502
- Waller ES, Sharanevych MA, Yakatan GJ (1982) "The effect of probenecid on nafcillin disposition." J Clin Pharmacol, 22, p. 482-9
- Shanson DC, McNabb R, Hajipieris P (1984) "The effect of probenecid on serum amoxycillin concentrations up to 18 hours after a single 3g oral dose of amoxycillin: possible implications for preventing endocarditis." J Antimicrob Chemother, 13, p. 629-32
- Sutherland R, Croydon EA, Rolinson GN (1972) "Amoxycillin: a new semi-synthetic penicillin." Br Med J, 3, p. 13-6
- Allen MB, Fitzpatrick RW, Barratt A, Cole RB (1990) "The use of probenecid to increase the serum amoxycillin levels in patients with bronchiectasis." Respir Med, 84, p. 143-6
- Gibaldi M, Schwartz MA (1968) "Apparent effect of probenecid on the distribution of penicillins in man." Clin Pharmacol Ther, 9, p. 345-9
Drug and food interactions
ampicillin food
Applies to: ampicillin / probenecid
ADJUST DOSING INTERVAL: Certain penicillins may exhibit reduced gastrointestinal absorption in the presence of food. The therapeutic effect of the antimicrobial may be reduced.
MANAGEMENT: The interacting penicillin should be administered one hour before or two hours after meals. Penicillin V and amoxicillin are not affected by food and may be given without regard to meals.
References (6)
- Neu HC (1974) "Antimicrobial activity and human pharmacology of amoxicillin." J Infect Dis, 129, s123-31
- Welling PG, Huang H, Koch PA, Madsen PO (1977) "Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects." J Pharm Sci, 66, p. 549-52
- McCarthy CG, Finland M (1960) "Absorption and excretion of four penicillins." N Engl J Med, 263, p. 315-26
- Cronk GA, Wheatley WB, Fellers GF, Albright H (1960) "The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract." Am J Med Sci, 240, p. 219-25
- Klein JO, Sabath LD, Finland M (1963) "Laboratory studies on oxacillin. I: in vitro activity against staphylococci and some other bacterial pathogens. II: absorption and urinary excretion in normal young." Am J Med Sci, 245, p. 399-411
- Neuvonen PJ, Elonen E, Pentikainen PJ (1977) "Comparative effect of food on absorption of ampicillin and pivampicillin." J Int Med Res, 5, p. 71-6
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.